Italy LASIK Eye Surgery Market Research Report: Size, Share, Trends & Forecast (2027-2033)

Italy LASIK Eye Surgery Market Overview

LASIK eye surgery in Italy is a laser procedure in which a femtosecond laser or microkeratome creates a corneal flap and an excimer laser reshapes the cornea to correct refractive error. Adults aged 18 to 45 with myopia or astigmatism mainly self-pay for it, alongside presbyopic patients. The Italy LASIK eye surgery market is forecast to grow at a compound annual growth rate (CAGR) of 4.47% between 2027 and 2033.

Key Highlights of the Italy LASIK Eye Surgery Market

• The Italy LASIK eye surgery market was valued at approximately USD 86 million in 2026. The market is estimated at approximately USD 90 million in 2027 and is projected to reach approximately USD 117 million by 2033.
• The market is forecast to expand at a CAGR of 4.47% between 2027 and 2033.
• By ablation planning technology, Refraction-Based LASIK led the market with a 55% share in 2026.
• Among the ablation planning technology segments, Ray-Tracing-Guided LASIK is the fastest-growing, expanding at a CAGR of 15% between 2027 and 2033.
• By primary treatment indication, Myopia Correction With or Without Myopic Astigmatism led the market with a 75% share in 2026,
• Among the primary treatment indications, Presbyopia Correction is the fastest-growing segment, expanding at a CAGR of 12% between 2027 and 2033.
• The market is fragmented, and the top five companies together hold a combined share of 19% in 2026.

The Italy LASIK eye surgery market is a privately paid, one-off procedure category in transition. Clinics once owned and run by individual surgeons are being combined into multi-site networks that sell laser correction alongside cataract and lens surgery. The end user is an adult who prefers a single payment to years of glasses and contact lenses, and the surgeon decides who qualifies after corneal screening.

Three forces decide how the Italy LASIK eye surgery market develops. A July 2026 review in Frontiers in Ophthalmology reported that 40.56% of Italian children aged 5 to 12 are short-sighted, so each cohort arrives with a larger pool of potential patients. Automated treatment planning is making outcomes more predictable and easier to standardise across sites. Household budgets set the limit, because the full price falls on the patient.

By the end of the forecast period, the Italy LASIK eye surgery market should be more concentrated in chain-operated sites, with growth coming from higher uptake per person and a wider patient age range rather than from more young adults. The Italian National Institute of Statistics (ISTAT) recorded 355,000 births in 2025, down 3.9%, so the younger cohort will not expand. That trajectory holds only if household purchasing power stabilises enough for self-paid surgery to remain affordable.

Market Drivers

Rising Myopia Across Younger Cohorts Enlarges the Pool of Adults Eligible for Laser Correction

Myopia is starting earlier and reaching a larger share of each cohort, and those children become the adults who qualify for laser correction between 18 and 45. For a myopic adult, LASIK ends the recurring cost and daily management of glasses and contact lenses in one procedure.

A February 2025 analysis in the British Journal of Ophthalmology, covering 276 studies and 5.41 million participants, put pooled childhood myopia prevalence at 35.81% and projected 39.80% by 2050. A July 2026 review in Frontiers in Ophthalmology reported 40.56% myopia among Italian children aged 5 to 12, a group that reaches the LASIK age band mainly in the later forecast years. Each additional myopic cohort translates into more eligibility screenings and surgical consultations at Italian refractive centres.

Through 2033, each forecast year adds older members of these cohorts to the 18 to 45 candidate pool, so consultation volumes rise even as the number of young adults falls. The driver stays commercially live because prevalence, not headcount, determines how many patients reach a screening. Together these shifts add eligible patients to the industry's consultation pipeline and support procedure demand across the forecast period.

Market Challenges

Fully Self Paid Surgery Meets a Squeeze on Household Purchasing Power

LASIK is an elective procedure, so the price is typically carried by the patient and every provider competes for the same discretionary household budget. Price-sensitive adults aged 25 to 44, including households with children, carry most of the cost pressure. Providers carry the effect as a lower share of consultations that convert into surgery, which makes the constraint structural rather than temporary.

ISTAT reported that household purchasing power fell 0.9% quarter on quarter in the second quarter of 2026, even as household disposable income rose 0.4%. In its June 2026 outlook, ISTAT projected household consumption growth of 0.6% for 2026, down from 1.1% in 2025. The Organisation for Economic Co-operation and Development (OECD) puts Italian out-of-pocket spending at almost 24% of health expenditure, against 15.5% across the European Union (EU), in its 2025 Country Health Profile.

Multi-site operators that can offer payment plans and package pricing are better placed to convert price-sensitive consultations, while independent practices carry the cost of idle laser capacity. Some price-sensitive demand shifts to postponed surgery, and consumption concentrates among households with stable income in the industry. The effect moderates the pace of growth through 2027 and 2028.

Recent Trends

Investor Backed Ophthalmic Chains Replace Single Practitioner Clinics

Italian refractive surgery was historically delivered by clinics owned by individual practitioners, with LASIK offered as one service within a general ophthalmic practice. Investor-backed networks now acquire independent clinics, standardise equipment and screening, and sell laser correction together with cataract and lens surgery under one brand. The change moves equipment and marketing decisions from the individual surgeon to the network.

In October 2024, Ardian, a private equity firm, completed the acquisition of a majority stake in Vista Vision, a Milan-based provider of laser vision correction and cataract surgery that then operated 12 clinics in Italy. In October 2025, EssilorLuxottica completed its acquisition of Optegra, an integrated platform of more than 70 eye hospitals and diagnostic facilities across five European countries, showing the same consolidation logic at larger scale.

Through 2033, laser and diagnostic suppliers will negotiate increasingly with network headquarters instead of individual surgeons, and patients will meet standardised screening and package pricing. Independent clinics will either join networks or specialise in complex cases. Within the industry, consolidation therefore concentrates demand for integrated laser and planning systems in fewer, larger procurement decisions.

Automated Ray Tracing Planning and AI Corneal Screening Reshape the LASIK Workflow

Conventional LASIK planning relies on a surgeon-selected nomogram built from manifest refraction, with measurements moved by hand between devices. Automated ray-tracing planning builds a three-dimensional optical model of each eye and calculates the ablation profile without manifest refraction. Artificial intelligence (AI) models applied to corneal tomography add a screening step that flags eyes at risk of ectasia.

A randomised fellow-eye study by the Heidelberg and Dresden university eye clinics, published in Ophthalmology in October 2025, treated 30 patients with Alcon Inc.'s automated ray-tracing LASIK in one eye and wavefront-optimized LASIK in the other. At three months, 100% of ray-tracing eyes were within 0.50 dioptres of target against 90%, and 100% reached 20/20 vision or better against 93.3%.

Adoption requires a site to run the vendor's own diagnostic device and laser, because the ray-tracing software depends on measurements from Alcon's Sightmap device. That ties each site to one platform and raises switching costs for single-surgeon practices, while networks with standard pathways can deploy one workflow across clinics. Italian use of ray-tracing LASIK is not yet documented, so near-term demand for these platforms comes first from multi-site operators, and suppliers with integrated planning systems gain differentiation.

Future Opportunities

Combined Laser and Lens Pathways Open Spectacle Independence for Presbyopic Adults

Adults in their late forties to sixties already pay for near-vision correction, but LASIK is marketed mainly to young myopic adults, so presbyopic patients are routed to lens surgery or stay in glasses. The gap persists because corneal presbyopia treatment is a compromise, lens replacement competes as the natural lens ages, and a branded combined pathway is not visible among Italian providers.

ISTAT reported that people aged 65 and over made up 25.1% of Italian residents on 1 January 2026, and the OneSight EssilorLuxottica Foundation Italy found in July 2025 that 95.9% of Italian presbyopes already use corrective tools while 72.3% report visual difficulties. Providers can capture this group through a bundled assessment that quotes laser and lens routes together, optician referral agreements and payment plans.

Execution requires surgeons trained in both corneal and lens procedures, a validated presbyopic ablation profile, and a single patient pathway that keeps people inside the network when a lens is the better option. Multi-service chains and hospital groups that run laser and cataract surgery together are positioned to move first, with pilots in 2027 and 2028 and volume building from 2030, adding a 45-plus patient group to demand in the industry.

Segmentation Analysis

By Ablation Planning Technology:

• Refraction-Based LASIK
  • Conventional LASIK
  • Wavefront-Optimized and Other Aspheric LASIK
• Wavefront-Guided LASIK
• Topography-Guided LASIK
• Ray-Tracing-Guided LASIK

Refraction-Based Planning Anchors 55% of Ablation Planning Demand

Refraction-Based LASIK leads because it runs on installed excimer platforms without extra diagnostic hardware, and surgeons already know its nomograms. The European Society of Cataract and Refractive Surgeons (ESCRS) Clinical Trends Survey, reported in 2025, found that 25% of more than 3,000 respondents mostly performed standard ablation and 19% wavefront-optimized ablation. Refraction-Based LASIK keeps its lead through 2033 unless industry networks move wholesale to automated planning.

In January 2025, Carl Zeiss Meditec AG received U.S. Food and Drug Administration (FDA) approval for the ZEISS MEL 90 excimer laser, whose single Triple-A ablation profile treats sphero-cylindrical errors and ablates one dioptre in as little as 1.3 seconds at 500 Hz, which keeps aspheric treatment fast and simple to plan.

Ray-Tracing-Guided LASIK is the fastest-growing planning technology at a CAGR of 15% between 2027 and 2033, as networks want repeatable outcomes across sites without a manual refraction step. In September 2026, SCHWIND eye-tech-solutions GmbH launched its Signature Line with ATRIUM Cloud and EASE at the ESCRS congress in London, adding connected laser planning. It grows faster than Refraction-Based LASIK because it expands from a small base each time a network standardizes its workflow.

By Primary Treatment Indication:

• Myopia Correction With or Without Myopic Astigmatism
• Hyperopia Correction With or Without Hyperopic Astigmatism
• Mixed Astigmatism Correction
• Presbyopia Correction

Myopia Correction Carries 75% of Treatment Demand

Myopia Correction leads because myopic adults aged 18 to 45 are the largest group presenting for refractive evaluation. In September 2026, Gruppo Refrattivo Italiano's Observatory on Vision reported, across more than 22,000 patients and 42,530 eyes, that 78.4% of those aged 18 to 45 were myopic, and that 26.4% of refractive surgery candidates had high myopia of at least 6 dioptres, where non-laser alternatives compete. The segment holds through 2033 unless high-myopia routing widens in the industry.

In September 2025, Alcon Inc. launched WaveLight Plus in the United States and Canada, a ray-tracing LASIK treatment for myopia with or without astigmatism, after earlier introduction in China and several European and Asia-Pacific markets, which shows new planning technology is being built first for myopic eyes.

Presbyopia Correction is the fastest-growing indication at a CAGR of 12% between 2027 and 2033, as laser vendors add dedicated presbyopic treatment modules for adults who do not belong to the young myopic pool. In August 2025, SCHWIND eye-tech-solutions GmbH detailed the PresbyMAX module of its AMARIS excimer laser family, which combines objective and subjective patient data and offers symmetric, micro-monovision and hybrid treatment modes. It grows faster than Myopia Correction because it expands from a small base into an older group that Myopia Correction demand does not reach.

Competitive Landscape

The industry is fragmented, with a large number of hospital groups, standalone ophthalmic clinics and single-practitioner centres competing for procedure volume. The top five companies held a combined share of 19% in 2026. The five companies profiled are Gruppo San Donato S.p.A., Neovision Tre Srl, Centro Oculistico Bresciano S.r.l. (Gruppo Refrattivo Italiano), Gruppo Villa Maria S.p.A. (Tiberia Hospital) and Humanitas Mirasole S.p.A. (Humanitas Research Hospital).

Key Companies in the Market

• Gruppo San Donato S.p.A.
• Neovision Tre Srl
• Centro Oculistico Bresciano S.r.l.
• Gruppo Villa Maria S.p.A.
• Humanitas Mirasole S.p.A.
• Fondazione Poliambulanza Istituto Ospedaliero
• SEKAL s.r.l. Micro Chirurgia
• Oculistica Pascotto
• Dott. Francesco Bisantis

Company Profiling

The following five companies are the leading participants in the industry, profiled by market connection, capacity and latest development.

Gruppo San Donato S.p.A. is a private hospital group operating from the Milan area, with ophthalmology linked to the San Raffaele hospital. It participates through the laser correction service at its Milan Respighi outpatient site, which treats refractive defects alongside the San Raffaele ophthalmology department. Capacity is not publicly disclosed, and the nearest verified metric is the Respighi site where the service is listed. No dated 2025 or 2026 LASIK launch has been published. The group acts as a hospital-anchored, referral-led participant.

Neovision Tre Srl operates within Neovision, which describes itself as the first Italian network of ophthalmic clinics, based in Milan. It participates through diagnostic work-ups and eye surgery for myopia, hyperopia, astigmatism and presbyopia at three Milan clinics. Surgical capacity is not publicly disclosed, and the nearest verified metric is those three Milan clinic sites. No dated 2025 or 2026 LASIK launch has been published. Neovision acts as a network-led, clinic-based provider.

Centro OculisticoBrescianoS.r.l. operates the refractive surgery centre of Gruppo Refrattivo Italiano from Via dei Mille 14 in Brescia, with clinical research in collaboration with the University of Brescia. It participates through laser refractive surgery, including Femto-LASIK and Presbyond, together with cataract and implantable lens surgery. Capacity is not publicly disclosed, and the nearest verified metric is its Brescia operating site. No dated 2025 or 2026 launch is published beyond its clinical dataset. It is a research-linked, specialist surgical provider.

Gruppo Villa Maria S.p.A. is a private hospital group whose Villa Tiberia Hospital in Rome runs an ophthalmology service that lists refractive surgery for myopia, hyperopia, astigmatism and presbyopia. It participates through that service, alongside cataract surgery. Capacity is not publicly disclosed, and the nearest verified metric is the Rome hospital site where the service is listed. No dated 2025 or 2026 LASIK launch has been published. The group acts as a hospital-based, regionally concentrated participant.

Humanitas Mirasole S.p.A. operates Humanitas Research Hospital in Rozzano, Milan, home to the Humanitas Centro Oculistico. It participates through laser refractive surgery for myopia, hyperopia, astigmatism and presbyopia on SCHWIND excimer and femtosecond lasers. Capacity is not publicly disclosed, and the nearest verified metric is one eye centre running both laser types. In May 2025, it published a refractive surgery patient guide describing how its lasers integrate several technologies and plan treatment from each eye's own aberration measurements. It acts as a technology-led, hospital-based provider.

News and Recent Developments

• In June 2026, Carl Zeiss Meditec AG and Aier Eye Hospital Group signed a strategic agreement for 25 VISUMAX 800 femtosecond laser systems, to be deployed from late 2026 across Aier's domestic and international networks. The agreement is in China, so it signals direction rather than Italian volume, but it shows a very large operator scaling lenticule extraction, the main non-LASIK substitute for myopic correction. The effect is to raise substitution risk for myopia-led LASIK volumes in the market, particularly among high-myopia candidates.